Home

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revision Previous revision
Next revision
Previous revision
home:protocol:olmesartan:safety [06.11.2019]
sallieq [Data supporting the safety of higher than typical dosing frequencies]
home:protocol:olmesartan:safety [07.19.2019] (current)
sallieq [Safety of olmesartan (Benicar)]
Line 1: Line 1:
    
 ====== Safety of olmesartan (Benicar) ====== ====== Safety of olmesartan (Benicar) ======
 +
 +<​relatedarticle>​ [[home:​diseases:​celiac#​recent_research|Recent research into Celiac disease]] </​article>​
  
 Some patients and healthcare providers have expressed concerns about the safety of higher than typical [[home:​mp:​olmesartan:​dosing|doses of olmesartan (Benicar)]]. Some patients and healthcare providers have expressed concerns about the safety of higher than typical [[home:​mp:​olmesartan:​dosing|doses of olmesartan (Benicar)]].
Line 122: Line 124:
  
 [[http://​doi.org/​10.5761/​atcs.oa.11.01691|angiotensin II and aldosterone are decreased in a change-over from candesartan to olmesartan]] [[http://​doi.org/​10.5761/​atcs.oa.11.01691|angiotensin II and aldosterone are decreased in a change-over from candesartan to olmesartan]]
 +
 +With the halt of reimbursement of olmesartan, there was a decrease in the prescription of ARB in France. When olmersartan was replaced by another ARB, a worse blood pressure control was observed in treated hypertensive patients. ​ (({{pubmed>​long:​29807620 }}))
 +
 +
 +==== Enteropathy ====
 +
 +The incidence of this adverse drug reaction is not entirely clear, although it is thought to be rare. 
 +(({{pubmed>​long:​26997446}}))
 +
 +
 +Seven cases (2.8%) reported recurrence of symptoms after restarting olmesartan (({{pubmed>​long:​31217979}}))
 +
 +Although enteropathy is rare, clinicians should remain vigilant of this potential adverse event even years after medication initiation. ​
 +(({{pubmed>​long:​31217979}}))
 +
 +results suggest that SMEEDS formulation improves dissolution and oral bioavailability of OM while reducing adverse effects (celiac-like enteropathy or diarrhea ). (({{pubmed>​long:​30986085}}))
 +
 +==== Collagenous enteritis, a genetic problem? ====
 +
 +Collagenous enteritis is an uncommon small intestinal injury pattern with unclear pathogenesis. ​
 +
 +All subjects with biopsy-proven collagenous enteritis diagnosed between 2002 and 2015 were identified from 2 tertiary care medical centers. Human leukocyte antigen (HLA)-DQ genotyping was performed by polymerase chain reaction on archived tissue. Celiac disease serology, past medical history, medications,​ smoking history, demographics,​ histology, clinical management, and follow-up were recorded. A total of 32 subjects were included. In contrast to celiac disease, subjects with collagenous enteritis were mostly elderly (median age at diagnosis, 69 y; range, 33 to 84 y). Seventy percent of collagenous enteritis subjects harbored celiac disease susceptibility alleles HLA-DQ2/​DQ8;​ however, only 1 subject had elevated serum levels of celiac disease-associated autoantibodies while on a gluten-containing diet. Furthermore,​ 56% of subjects were taking nonsteroidal anti-inflammatory drugs, 36% proton-pump inhibitors, 28% statins, and 32% olmesartan at the time of diagnosis. Discontinuation of olmesartan and treatments with steroids and/or gluten-free diet resulted in symptomatic and histologic improvement. (({{pubmed>​long:​29324472 }}))
 +
 +Olmesartan was not associated with intestinal malabsorption or significant body weight loss in the general Korean population. ​ (({{pubmed>​long:​29172402}}))
  
 ===== Notes and comments ===== ===== Notes and comments =====
home/protocol/olmesartan/safety.1560223396.txt.gz · Last modified: 06.11.2019 by sallieq
© 2015, Autoimmunity Research Foundation. All Rights Reserved.